42 / 43
CONCLUSIONS
Nivolumab-ipilimumab is superior to sunitinib in OS with 30% of
long survivors
This benefit especially relates to PD-L1-positive patients.
11% of intermediate and high-risk patients experience a
complete response and 18% in sarcomatoid hIstologies!!
Toxicity profile appears to be manageable, but be aware of
immune-related AE.
Leads to fewer symptoms and better HRQoL
Nivolumab-ipilimumab should be a new SOC in intermediate
and poor-risk patients.